AbbVie (ABBV) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $0.1.
- AbbVie's EPS (Weighted Average and Diluted) fell 8863.64% to $0.1 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.32, marking a year-over-year decrease of 5416.67%. This contributed to the annual value of $2.42 for FY2024, which is 1112.6% down from last year.
- AbbVie's EPS (Weighted Average and Diluted) amounted to $0.1 in Q3 2025, which was down 8863.64% from $0.53 recorded in Q2 2025.
- In the past 5 years, AbbVie's EPS (Weighted Average and Diluted) registered a high of $2.51 during Q1 2022, and its lowest value of -$0.01 during Q4 2024.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was $0.77 (2024), whereas its average is $1.03.
- As far as peak fluctuations go, AbbVie's EPS (Weighted Average and Diluted) soared by 2230155.25% in 2021, and later plummeted by 10279.13% in 2024.
- Over the past 5 years, AbbVie's EPS (Weighted Average and Diluted) (Quarter) stood at $2.28 in 2021, then crashed by 38.92% to $1.39 in 2022, then tumbled by 66.57% to $0.46 in 2023, then plummeted by 102.79% to -$0.01 in 2024, then skyrocketed by 870.87% to $0.1 in 2025.
- Its EPS (Weighted Average and Diluted) stands at $0.1 for Q3 2025, versus $0.53 for Q2 2025 and $0.72 for Q1 2025.